Dr. Ralph M. Wirtz is a leading international molecular biologist who is very successfully involved in various research and development projects, all of which improve and develop innovative technologies to combat oncological diseases and make them available for patients. Notably, he has been involved in the successful development of small molecule-based, targeted therapies against kidney and bladder cancer up to FDA approval and market launch.
Since 2010, he serves as CEO of STRATIFYER Molcular Pathology GmbH, a company that develops molecular testing methods for in vitro diagnostics, is responsible for study design and translational conduction of clinical studies. He has founded and leads a number of interdisciplinary professional cancer organizations for individualized medicine. Moreover, he is active as CSO of RadioVaxX GmbH. Dr. Ralph M. Wirtz has built up a worldwide network that translates deep insights into tumor biology from clinical trials into personalized medicine approaches via molecular registries into Real World application. Of particular importance are the molecular Real World Experience registries in bladder and prostate cancer (Bladder BRIDGister, Prostate BRIDGister) bridging the gap between molecular science and real-world cancer care across all continents.
